Oryzon Genomics SA (ORYZF)
3.27
0.00 (0.00%)
USD |
OTCM |
Sep 04, 16:00
Oryzon Genomics Research and Development Expense (Quarterly) : 6.445M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 6.445M |
| March 31, 2026 | 5.265M |
| December 31, 2025 | 5.121M |
| September 30, 2025 | 3.840M |
| June 30, 2025 | 2.925M |
| March 31, 2025 | |
| December 31, 2024 | |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | 4.294M |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | 4.278M |
| Date | Value |
|---|---|
| March 31, 2022 | |
| September 30, 2021 | 3.982M |
| June 30, 2021 | 3.026M |
| March 31, 2021 | 4.336M |
| December 31, 2020 | 0.3422M |
| September 30, 2020 | 0.4184M |
| June 30, 2020 | |
| March 31, 2020 | 4.076M |
| December 31, 2019 | 0.2712M |
| September 30, 2019 | 0.2824M |
| June 30, 2019 | 0.2764M |
| March 31, 2019 | 2.612M |
| December 31, 2018 | 2.298M |
| September 30, 2018 | 1.969M |
| June 30, 2018 | 2.152M |
| March 31, 2018 | 2.335M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Pharma Mar SA | 30.67M |
| Grifols SA | 99.99M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alkermes Plc | 111.12M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |